Ligand Pharmaceuticals Inc.(LGND)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LGND Ligand Pharmaceuticals Inc.

交易中 06-02 11:57:30 EDT

232.38

+2.60

+1.13%

最高232.58	最低227.76	成交量6.65万
今开229.43	昨收229.78	日振幅2.10%
总市值46.57亿	流通市值45.22亿	总股本2,004万
成交额1,531万	换手率0.34%	流通股本1,946万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LGND","market":"US","secType":"STK","nameCN":"Ligand Pharmaceuticals Inc.","latestPrice":232.38,"timestamp":1780415843008,"preClose":229.78,"halted":0,"volume":66498,"delay":0,"changeRate":0.01131517103316213,"floatShares":19457600,"shares":20041061,"eps":7.499522,"marketStatus":"交易中","change":2.6,"latestTime":"06-02 11:57:30 EDT","open":229.43,"high":232.5799,"low":227.76,"amount":15308374.24392,"amplitude":0.020976,"askPrice":232.38,"askSize":11,"bidPrice":231.21,"bidSize":3,"shortable":3,"etf":0,"ttmEps":7.499522,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780430400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":721976400000,"exchange":"NASDAQ","adjPreClose":229.78,"postHourTrading":{"tag":"盘后","latestPrice":229.78,"preClose":229.78,"latestTime":"16:10 EDT","volume":3779,"amount":868334.16,"timestamp":1780344605353,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.978071,"impliedVol":0.3936,"impliedVolPercentile":0.6016},"requestUrl":"/m/hq/s/LGND","defaultTab":"news","newsList":[{"id":"1137746136","title":"Orchestra BioMed获Ligand 1500万美元战略投资，此前协议正式落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1137746136","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137746136?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:01","pubTimestamp":1778068908,"startTime":"0","endTime":"0","summary":"根据早前公布的战略融资协议，生物医药公司Orchestra BioMed（简称OBIO）已成功获得其合作伙伴Ligand Pharmaceuticals（简称LGND）提供的1500万美元投资。\n此次注资标志着双方战略合作进入实质性阶段，资金将用于加速Orchestra BioMed核心创新疗法的研发与商业化进程。该笔投资遵循了既定的协议条款，体现了Ligand对Orchestra BioMed技术平台与长期增长潜力的持续信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDT","LU0208291251.USD","LU0314106906.USD","IE00BFXG1179.USD","BK4007","LU2089984988.USD","LGND","LU2111349929.HKD","BK4566","IE00BQXX3C00.GBP","LU2089284900.SGD","LU2089283258.USD","BK4533","LU0158827948.USD","LU1023059063.AUD","LU0211331839.USD","LU0496365809.HKD","IE00B3PB1722.GBP","BK4588","LU1989764664.SGD","BK4585","LU0320765489.SGD","LU1244550494.USD","LU0162691827.USD","LU2271345857.HKD","LU2023251221.USD","IE00BQXX3D17.EUR","LU0566484027.USD","IE00B42XCP33.USD","LU0976567544.SGD","IE0009354923.USD","LU1571399168.USD","BK4139","IE00BQXX3F31.USD","LU1244550221.USD","LU2112291526.USD","LU0006306889.USD","LU1983299246.USD","LU0072461881.USD","LU1244550577.SGD","LU1989771016.USD","IE00BVYPNW00.USD","LU2468319806.SGD","LU0158827781.USD","LU0265550359.USD","LU1061106388.HKD","IE000M9KFDE8.USD","LU0106261372.USD","LU0122379950.USD","LU1116320737.USD","IE00B3T34201.USD","IE00BDGV0183.EUR","LU0211326755.USD","LU1291159041.SGD","LU1506573853.SGD","LU2028103732.USD","LU0265550946.USD","LU1989764748.USD","LU1057294990.SGD","IE00BGHQF631.EUR","LU0211326839.USD","LU0070302665.USD","BK4082","LU0432979614.USD","LU1116320901.HKD","OBIO","IE00BVYPNV92.GBP","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175038706","title":"财报前瞻｜Ligand Pharmaceuticals Inc.营收或增51.92%，机构看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1175038706","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175038706?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:39","pubTimestamp":1777509543,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.将于2026年05月07日盘前发布最新财报，市场聚焦并购进展及盈利动能的延续性。市场一致预期本季度公司营收为5,879.59万美元，同比增长51.92%；调整后每股收益为1.82美元，同比增长50.21%；息税前利润为2,103.48万美元，同比增长574.93%；公司上季度未披露针对本季度的明确收入或利润指引，毛利率与净利率暂无一致预期可引用。近期机构立场以看多为主，占比接近100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Ligand Pharmaceuticals Inc.营收或增51.92%，机构看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182308829","title":"Ligand制药上调2026年营收指引至2.7-3.1亿美元 特许权使用费达2.25-2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182308829","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182308829?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:09","pubTimestamp":1777288184,"startTime":"0","endTime":"0","summary":"Ligand制药公司近日宣布大幅上调2026年财务预期，将全年营收指引区间调整为2.7亿至3.1亿美元。其中特许权使用费收入预计将贡献2.25亿至2.5亿美元，展现出公司核心授权业务强劲的增长动能。\n这一乐观预测主要得益于其合作药企多项创新药物的商业化进展超预期。通过精准的授权合作模式，Ligand持续扩大其生物技术资产组合的价值变现能力。此次指引上调也反映出市场对其合作伙伴研发管线商业化前景的积极预期。\n作为专注医药特许权投资的企业，XOMA公司通过持有Ligand相关权益间接受益于这一利好消息。生物医药领域特许权经营模式的成熟发展，正为行业带来更可持续的增长路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LGND","LU1559883803.SGD","BK4139","XOMA","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106361138","title":"Ligand调升2026年调整后每股收益指引至8.50-9.50美元 预计2027年将带来1.50美元增值","url":"https://stock-news.laohu8.com/highlight/detail?id=1106361138","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106361138?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287789,"startTime":"0","endTime":"0","summary":"生物制药企业Ligand Pharmaceuticals Inc.宣布上调2026财年业绩预期，将调整后每股收益预测区间从原先的8.00-9.00美元提升至8.50-9.50美元。此次修正主要基于公司核心特许经营权业务的强劲表现及里程碑款项的加速确认。值得注意的是，管理层同时发布2027年业绩展望，预期通过现有合作项目的推进与新授权协议的落地，调整后每股收益将获得1.50美元的额外增长。Ligand此次指引上调或将对拥有相关权益资产的投资组合产生积极影响，进一步巩固其在 royalty-based 商业模式中的战略地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LU1559883803.SGD","LU0566484027.USD","XOMA","LGND","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147877354","title":"Ligand收购XOMA特许权 加速盈利增长并巩固其作为领先生物制药特许权整合商的地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1147877354","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147877354?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:02","pubTimestamp":1777287743,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.（纳斯达克：LGND）宣布将收购XOMA Corp（纳斯达克：XOMA）的特许权资产，这一战略举措预计将显著推动其盈利增长。通过此次收购，Ligand将进一步巩固其在生物制药领域作为领先特许权整合商的地位。\n该交易将增强Ligand的特许权组合，为其带来更稳定的现金流和多元化的收入来源。作为生物制药特许权领域的重要参与者，Ligand通过此次收购展示了其在行业内的战略布局能力。市场观察人士认为，这一动作将提升Ligand在资本市场的吸引力，并为长期价值创造奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE0009354923.USD","LGND","XOMA","LU1559883803.SGD","BK4139","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103933018","title":"美国银行全球研究首次覆盖Ligand制药 给予买入评级 目标价244美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103933018","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103933018?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:40","pubTimestamp":1773236411,"startTime":"0","endTime":"0","summary":"美国银行全球研究（Bofa Global Research）宣布，首次将Ligand Pharmaceuticals Inc.纳入研究覆盖范围，并给予其“买入”评级。该机构为这家生物制药公司设定了244美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0566484027.USD","LGND","IE0009354923.USD","LU1559883803.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616392966","title":"Ligand Pharmaceuticals Incorporated涨0.95% 股价突破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2616392966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616392966?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:00","pubTimestamp":1772463609,"startTime":"0","endTime":"0","summary":"北京时间2026年03月02日23时00分，Ligand Pharmaceuticals Incorporated股票出现异动，股价急速拉升0.95%。截至发稿，该股报200.19美元/股，成交量1.5774万股，换手率0.08%，振幅1.20%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体跌幅为0.62%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302230009a442a1d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302230009a442a1d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","LGNZZ","LU1559883803.SGD","BK4007","LGND","LGNDZ","LU0566484027.USD","LGNYZ","BK4139","LGNXZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168108582","title":"财报前瞻 ｜Ligand Pharmaceuticals Inc.本季度营收预计同比增42.45%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1168108582","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168108582?lang=zh_cn&edition=full","pubTime":"2026-02-19 12:59","pubTimestamp":1771477147,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.将于2026年02月26日发布最新季度财报，市场预期营收与盈利维持增长态势，研发与授权里程碑进展被高度关注。市场一致预期本季度Ligand Pharmaceuticals Inc.营收约为5,558.89万美元，同比增长42.45%；调整后每股收益约为1.56美元，同比增长31.21%；息税前利润约为2,182.98万美元，同比增长124.63%。上季度Ligand Pharmaceuticals Inc.营收为8,689.20万美元，同比增长67.71%；毛利率为78.50%；归属于母公司股东的净利润为1.17亿美元，同比增长2,319.50%；净利率为101.57%；调整后每股收益为3.09美元，同比增长67.94%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Ligand Pharmaceuticals Inc.本季度营收预计同比增42.45%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518275372","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275372","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518275372?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:02","pubTimestamp":1741615340,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时02分，Ligand Pharmaceuticals Incorporated股票出现波动，股价快速下挫5.12%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为668.89%、329.35%、92.62%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220221abf30860&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220221abf30860&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNYZ","LGNDZ","LGNZZ","LGNXZ","LU1559883803.SGD","LU0566484027.USD","BK4007","BK4139","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517145817","title":"Ligand Pharmaceuticals Incorporated2024财年实现净利润-4.03百万美元，同比减少107.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145817?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Ligand Pharmaceuticals Incorporated公布财报，公告显示公司2024财年净利润为-4.03百万美元，同比减少107.49%；其中营业收入为1.67亿美元，同比增加27.48%，每股基本收益为-0.22美元。从资产负债表来看，Ligand Pharmaceuticals Incorporated总负债1.11亿美元，其中短期债务1.29百万美元，资产负债比为8.49，流动比率为0.09。机构评级：截至2025年3月8日，当前有7家机构对Ligand Pharmaceuticals Incorporated目标价做出预测，其中目标均价为144.86美元，其中最低目标价为125.00美元，最高目标价为160.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000045a2647e57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000045a2647e57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNXZ","LGNYZ","LGND","LGNDZ","LGNZZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630569","title":"Ligand Pharmaceuticals Incorporated盘中异动 股价大跌5.06%报116.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630569","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630569?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:15","pubTimestamp":1741014937,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时15分，Ligand Pharmaceuticals Incorporated股票出现波动，股价快速下挫5.06%。截至发稿，该股报116.05美元/股，成交量1.4762万股，换手率0.08%，振幅4.65%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体跌幅为0.09%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032315379637b830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032315379637b830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1559883803.SGD","BK4139","LGNYZ","BK4007","LU0566484027.USD","LGND","LGNDZ","LGNZZ","LGNXZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195157340","title":"异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1195157340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195157340?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:26","pubTimestamp":1740763592,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.(LGND)股价今日盘中大涨5.07%,引起市场关注。消息显示,这家生物制药公司最新财报业绩表现优异,推动其股价上涨。\n\n公司最新披露的财报数据显示,Ligand Pharmaceuticals上一季度实现营收5181万美元,毛利4111万美元。尽管出现小幅净亏损,但公司营收和毛利润均保持较高水平,体现出公司运营获利能力不俗。\n\n此外,机构对该公司前景也持看好态度。目前有7家机构给予Ligand Pharmaceuticals股票\"买入\"评级,评级比例高达100%,反映市场对其长期增长信心充足。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516372598","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.07%报121.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516372598?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:07","pubTimestamp":1740762443,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日01时07分，Ligand Pharmaceuticals Incorporated股票出现异动，股价大幅拉升5.07%。截至发稿，该股报121.54美元/股，成交量3.4864万股，换手率0.18%，振幅4.47%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体涨幅为0.47%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301010723a2582793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301010723a2582793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LGNYZ","LU0566484027.USD","LGND","LU1559883803.SGD","LGNZZ","LGNDZ","LGNXZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167626655","title":"异动解读 | LGND 2024年Q4财报超预期,股价盘中大涨6.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167626655","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167626655?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:32","pubTimestamp":1740670354,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.今日盘中股价大涨6.32%,引发市场广泛关注。根据相关报道,LGND公司2024年第四季度财报数据超出分析师预期,成为推动股价上涨的主因。总的来说,LGND今日股价大涨与其财报业绩表现优异有直接关系,业绩超预期成为助推股价上行的主导力量。投资者乐观看好该公司未来发展前景,推动了LGND股价在盘中出现大涨行情。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514810543","title":"Ligand Pharmaceuticals Incorporated盘中异动 大幅上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514810543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514810543?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669808,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Ligand Pharmaceuticals Incorporated股票出现波动，股价快速拉升5.18%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为885.78%、177.60%、104.84%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232328a256879a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232328a256879a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0566484027.USD","LGNYZ","LGNDZ","LGNZZ","LGND","BK4139","LGNXZ","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191904562","title":"Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19，销售额$4281万 超过预估的$3902万","url":"https://stock-news.laohu8.com/highlight/detail?id=1191904562","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191904562?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:08","pubTimestamp":1740658089,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals公布季度每股收益为$1.27，超过分析师共识预估的$1.19，高出6.72%。相比去年同期每股收益$1.38，下降了7.97%。以上内容来自Benzinga Earnings专栏，原文如下：Ligand Pharmaceuticals  reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 7.97 percent decrease over earnings of $1.38 per share from the same period last year.  The company reported quarterly sales of $42.81 million which beat the analyst consensus estimate of $39.02 million by 9.71 percent.  This is a 52.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19，销售额$4281万 超过预估的$3902万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511110836","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511110836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511110836?lang=zh_cn&edition=full","pubTime":"2025-02-15 03:40","pubTimestamp":1739562048,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日03时40分，Ligand Pharmaceuticals Incorporated股票出现波动，股价急速上涨5.22%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体跌幅为0.60%。其相关个股中，Moleculin Biotech, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Allogene Therapeutics, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3111.92%、792.89%、621.89%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为74.35%、71.65%、66.45%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150340489885ce50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150340489885ce50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNZZ","LGNYZ","LGNDZ","LGNXZ","LGND","BK4007","BK4139","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505166784","title":"Ligand Pharmaceuticals Incorporated盘中异动 快速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505166784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505166784?lang=zh_cn&edition=full","pubTime":"2025-01-22 05:01","pubTimestamp":1737493262,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日05时01分，Ligand Pharmaceuticals Incorporated股票出现异动，股价大幅拉升5.04%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体涨幅为1.82%。其相关个股中，Dogwood Therapeutics, Inc.、Camp4 Therapeutics Corporation、Channel Therapeutics Corporation涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为1799.35%、534.10%、193.14%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Revolution Medicines Inc C/Wts 17/12/2026 ，振幅分别为103.72%、96.32%、69.14%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122050102abb39826&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122050102abb39826&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGND","BK4007","LGNZZ","LU0566484027.USD","LU1559883803.SGD","LGNYZ","LGNXZ","LGNDZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502289210","title":"Ligand Pharmaceuticals Incorporated盘中异动 临近午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502289210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502289210?lang=zh_cn&edition=full","pubTime":"2025-01-11 00:56","pubTimestamp":1736528167,"startTime":"0","endTime":"0","summary":"北京时间2025年01月11日00时56分，Ligand Pharmaceuticals Incorporated股票出现异动，股价快速下挫5.05%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体跌幅为1.75%。其相关个股中，Conduit Pharmaceuticals Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Omniab Inc C/Wts 涨幅较大，Zyversa Therapeutics, Inc.、Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.较为活跃，换手率分别为1213.88%、804.34%、226.94%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Conduit Pharmaceuticals Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为108.20%、100.85%、64.55%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250111005608986206f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250111005608986206f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LGNYZ","LU0566484027.USD","LU1559883803.SGD","LGND","LGNZZ","LGNXZ","LGNDZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2494335557","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494335557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494335557?lang=zh_cn&edition=full","pubTime":"2024-12-28 01:37","pubTimestamp":1735321061,"startTime":"0","endTime":"0","summary":"北京时间2024年12月28日01时37分，Ligand Pharmaceuticals Incorporated股票出现异动，股价大幅跳水5.26%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中，整体跌幅为0.61%。其相关个股中，Abpro Holdings, Inc、Vor Biopharma Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Evaxion Biotech As、Scisparc Ltd.、Neuphoria Therapeutics Inc.较为活跃，换手率分别为120.96%、59.02%、51.83%，振幅较大的相关个股有Nkgen Biotech Inc C/Wts 31/05/2028、Galectin Therapeutics Inc.、Abpro Holdings, Inc，振幅分别为147.50%、65.39%、62.45%。Ligand Pharmaceuticals Incorporated公司简介：Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122801374295ef9a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122801374295ef9a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU1559883803.SGD","LGNZZ","LGNYZ","LGNXZ","LU0566484027.USD","LGNDZ","LGND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ligand.com","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.125},{"period":"6month","weight":0.1904},{"period":"1year","weight":1.2486},{"period":"ytd","weight":0.2153}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ligand Pharmaceuticals Incorporated于1987年在特拉华州注册，是一家生物制药公司。公司商业模式为，开发或收购能产生收益的资产，将其融合到精益企业的成本结构中。公司的目标是创造可持续盈利的业务以生成股东价值。由于公司的商业模式是基于与其他制药公司合作，商业化利用并销售资产，因此公司不少收入来自合作伙伴提供的相关使用费。公司认识到了制药行业药物重制的重要性，2011年将CAPTISOL项目加入到技术投资中。CAPTISOL是一个功能强大的配方技术，拥有5个美国食品药品管理局批准的产品，包括Pfizer公司的VFEND IV和Baxter International公司的Nexterone，以及其他一些在临床阶段投入使用的合作伙伴项目。与同行的其他公司相比，公司已经组建了一个最大的行业多元化资产组合，在未来能产生显著的收益。资产组合中发展的治疗方案可以解决许多尚未得到解决的医疗需求缺口，包括肝炎、肌肉萎缩、老年痴呆症、血脂异常、糖尿病、贫血、哮喘、类风湿关节炎、和骨质疏松症。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.005806},{"month":2,"riseRate":0.483871,"avgChangeRate":0.01809},{"month":3,"riseRate":0.548387,"avgChangeRate":0.028437},{"month":4,"riseRate":0.548387,"avgChangeRate":0.011356},{"month":5,"riseRate":0.483871,"avgChangeRate":0.022002},{"month":6,"riseRate":0.625,"avgChangeRate":0.056747},{"month":7,"riseRate":0.483871,"avgChangeRate":-0.009004},{"month":8,"riseRate":0.548387,"avgChangeRate":-0.017853},{"month":9,"riseRate":0.387097,"avgChangeRate":0.004496},{"month":10,"riseRate":0.6,"avgChangeRate":0.000952},{"month":11,"riseRate":0.5,"avgChangeRate":0.026577},{"month":12,"riseRate":0.645161,"avgChangeRate":0.046708}],"exchange":"NASDAQ","name":"Ligand Pharmaceuticals Inc.","nameEN":"Ligand Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ligand Pharmaceuticals Inc.(LGND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ligand Pharmaceuticals Inc.(LGND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ligand Pharmaceuticals Inc.,LGND,Ligand Pharmaceuticals Inc.股票,Ligand Pharmaceuticals Inc.股票老虎,Ligand Pharmaceuticals Inc.股票老虎国际,Ligand Pharmaceuticals Inc.行情,Ligand Pharmaceuticals Inc.股票行情,Ligand Pharmaceuticals Inc.股价,Ligand Pharmaceuticals Inc.股市,Ligand Pharmaceuticals Inc.股票价格,Ligand Pharmaceuticals Inc.股票交易,Ligand Pharmaceuticals Inc.股票购买,Ligand Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ligand Pharmaceuticals Inc.(LGND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ligand Pharmaceuticals Inc.(LGND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}